新華醫療(600587.SH):2021年度淨利預增126.36%-171.63%
格隆匯1月28日丨新華醫療(600587.SH)公佈2021年年度業績預增公吿,公司預計2021年度實現歸屬於上市公司股東的淨利潤為5.3億元至6.36億元,與上年同期(法定披露數據)相比,增加2.96億元至4.02億元,同比增長126.36%至171.63%。
公司預計2021年度實現歸屬於上市公司股東的扣除非經常性損益的淨利潤為3.8億元至4.56億元,與上年同期(法定披露數據)相比,增加1.85億元到2.61億元,同比增長94.83%至133.79%。
業績預增的主要原因:
(一)主營業務影響:報吿期內,公司貫徹落實“調結構強主業提效益防風險”工作指導方針和高質量發展總基調,聚焦主業,集中優勢資源重點發展醫療器械、製藥裝備等板塊的製造類產品,持續深入開展提質增效,優化公司產品結構,提高毛利率水平,公司盈利能力提升。
(二)非經常性損益影響:1、受公司股票價格變動影響,公司凍結的隋湧等9名自然人持有的新華醫療股票公允價值較上年同期增長,公允價值變動收益增加。2、報吿期內,公司加快資源整合,優化產業結構,主動出清低效資產、虧損資產,掛牌出售了淄博淄川區醫院西院有限公司、上海欣航實業有限公司、上海聚力通供應鏈有限公司等公司的股權,投資收益增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.